A Research Guide for
Multiple Myeloma

Multiple myeloma causes harm in several specific ways, and oncologists use the acronym CRAB to describe the organ damage that indicates active disease requiring treatment: Calcium elevation, Renal (kidney) damage, Anemia, and Bone disease. Understanding each helps you recognize warning signs and make sense of your monitoring schedule.

C — Calcium elevation (hypercalcemia): Myeloma cells stimulate bone-destroying osteoclasts (and suppress bone-forming osteoblasts) through signaling molecules called RANK-L and DKK-1. As bone breaks down faster than it reforms, calcium is released from bone into the bloodstream. High calcium levels cause symptoms including extreme thirst, frequent urination, constipation, confusion, fatigue, and nausea. Hypercalcemia can be dangerous (affecting heart rhythm and kidney function) and is a medical emergency when severe. Treatment includes aggressive IV fluids, bisphosphonates (zoledronic acid), and starting myeloma therapy to suppress the underlying disease.

R — Renal impairment: About 20–25% of myeloma patients have some degree of kidney damage at diagnosis, and up to 50% develop it at some point during their disease. The two main causes are: (1) light chain cast nephropathy, where the excess monoclonal light chains (specifically lambda or kappa) produced by myeloma cells filter through the kidney and clog the tubules, causing obstruction and scarring; and (2) hypercalcemia-induced kidney damage. Adequate hydration (aim for 2+ liters of fluid per day unless your doctor limits this for other reasons) is one of the simplest ways to protect the kidneys. Bortezomib-based regimens are preferred in patients with severe renal impairment because bortezomib does not require renal dose adjustment the way lenalidomide does. Kidney function often recovers substantially with effective myeloma treatment.

A — Anemia: Myeloma cells crowd out normal blood cell precursors in the bone marrow, reducing the production of red blood cells. They also release cytokines that suppress red cell production. Anemia causes fatigue, shortness of breath, dizziness, and reduced exercise tolerance. Your hemoglobin level will be monitored regularly. Treatment is primarily directed at the myeloma itself; erythropoiesis-stimulating agents (ESAs) and blood transfusions are sometimes used supportively when anemia is severe.

B — Bone disease: Osteolytic (bone-dissolving) lesions are the hallmark of myeloma bone disease, appearing on imaging as “punched-out holes.” They occur because myeloma tips the balance in bone remodeling strongly toward destruction. Lesions can cause bone pain (most commonly in the back or ribs), pathological fractures (bones breaking with minimal trauma), and compression fractures of the vertebrae. Bone-protective agents — intravenous zoledronic acid (Zometa) or subcutaneous denosumab (Xgeva) — are recommended for virtually all myeloma patients on active therapy. These agents reduce the risk of skeletal events by roughly 30–40%. Dental care before starting bisphosphonate therapy is important (osteonecrosis of the jaw is a rare but serious complication).

Beyond CRAB, the updated IMWG (International Myeloma Working Group) diagnostic criteria also recognize SLiM criteria as indications to treat: a bone marrow plasma cell percentage ≥60%, a serum free light chain ratio ≥100, and >1 focal lesion on MRI. These criteria were added because studies showed patients with these findings had a >80% risk of developing CRAB damage within 2 years, so early treatment improves outcomes even before damage occurs.

One of the most confusing aspects of myeloma for newly diagnosed patients is understanding what the blood tests actually measure — and why your doctor is watching specific numbers so closely. Myeloma cells produce an abnormal protein called M-protein (also called monoclonal protein, paraprotein, or M-spike), and tracking this protein is how your care team knows whether the myeloma is responding to treatment, stable, or growing.

What is M-protein? Normal plasma cells produce immunoglobulins (antibodies) in a diverse, polyclonal pattern — each clone makes a slightly different antibody against different threats. In myeloma, one clone has taken over and is making vast quantities of a single, identical immunoglobulin (the M-protein) that does not protect against infection. The M-protein itself is usually not directly toxic, but it’s a marker of myeloma cell burden. When myeloma is responding to treatment, the M-protein level falls. When it’s growing, the M-protein rises.

Types of myeloma by protein produced:

• IgG myeloma (~52% of cases): Produces M-protein consisting of IgG immunoglobulin. Generally milder course; less prone to light chain kidney damage.
• IgA myeloma (~20%): Produces IgA. Slightly higher risk of hyperviscosity (blood thickening) from high IgA levels. Often migrates on protein electrophoresis, making measurement sometimes tricky.
• Light chain myeloma (~15%): Produces only the light chain portion of the antibody (kappa or lambda), not the full immunoglobulin. These don’t show up on serum protein electrophoresis — instead measured by serum free light chain assay and urine protein electrophoresis (UPEP). Higher risk of kidney damage.
• IgD/IgM/IgE (<2% each): Rare subtypes; IgD and IgM often have distinctive presentations.
• Non-secretory myeloma (~1–3%): Myeloma cells don’t produce detectable M-protein. Monitored by bone marrow biopsy and imaging rather than blood protein levels. Requires imaging-based response assessment.

Serum protein electrophoresis (SPEP) and immunofixation (SIFE): SPEP separates proteins in your blood by size and charge, showing the M-spike as a narrow peak. It quantifies the M-protein level in g/dL. Immunofixation (SIFE) identifies the type (IgG kappa? Lambda? etc.) but cannot quantify. Your oncologist uses SPEP to track response and immunofixation to confirm whether M-protein is still detectable at all (important for defining “complete response,” which requires a negative immunofixation).

Serum free light chain (SFLC) assay: Measures the unbound (free) kappa and lambda light chains in the blood, and the ratio between them. In myeloma, the involved free light chain (the one produced by the myeloma clone) is elevated, and the ratio is abnormal. The SFLC assay is particularly important for light chain myeloma (where SPEP may be normal) and for monitoring MRD and early relapse. Normal kappa:lambda ratio is 0.26–1.65. In lambda myeloma, the ratio is <0.26; in kappa myeloma, >1.65.

Urine tests (UPEP, UIFE): 24-hour urine protein electrophoresis (UPEP) and urine immunofixation (UIFE) are collected to measure Bence Jones proteins (free light chains excreted in urine). These are most important in light chain and nonsecretory myeloma. The urine collection must be done precisely (24-hour collection starting with discarding the first morning void and ending with the next morning’s void). Inadequate collection is a common error; ask your nurse to review the technique with you.

Following your numbers over time: At diagnosis, your myeloma is characterized by its M-protein level and type. During treatment, serial measurements every 3–4 weeks track whether the M-protein is falling (responding), stable, or rising (progressing). A 25% rise in M-protein (or any new CRAB criteria) triggers the definition of “progressive disease” and warrants consideration of treatment change. A 90% fall in M-protein = VGPR. Undetectable on immunofixation = CR. Keep a personal log of your M-protein trend — many patients find this empowering, and it helps you catch laboratory issues (hemolysis, dilution errors) that can cause apparent fluctuations.

Unlike staging in colon or lung cancer (which reflects how far the tumor has spread), staging in multiple myeloma does not map directly to “how far it has spread” — myeloma is already throughout the bone marrow at diagnosis. Instead, myeloma staging predicts how aggressive the disease is likely to behave and informs prognosis. Two staging systems are used:

ISS (International Staging System): Uses two blood markers — serum beta-2 microglobulin (B2M) and serum albumin. Stage I: B2M <3.5 mg/L and albumin ≥3.5 g/dL (best prognosis). Stage II: neither Stage I nor Stage III criteria. Stage III: B2M ≥5.5 mg/L (worst prognosis). The ISS was developed in 2005 and remains widely used for its simplicity.

R-ISS (Revised International Staging System): Adds two additional factors to the ISS: (1) high-risk chromosomal abnormalities detected by FISH (specifically: del[17p], t[4;14], t[14;16]), and (2) elevated serum LDH (a marker of aggressive cell proliferation). R-ISS Stage I = ISS Stage I + standard-risk cytogenetics + normal LDH (best prognosis, median OS >10 years in clinical trials). R-ISS Stage III = ISS Stage III + high-risk cytogenetics or elevated LDH (median OS ~4–5 years in older studies, improving with current therapies). Stage II is everything in between.

Why cytogenetics matters: The chromosomal changes in your myeloma cells significantly predict how the disease will respond to standard treatment. High-risk cytogenetics are found in about 20–25% of newly diagnosed patients. The most important high-risk changes are:

• del(17p): Deletion of chromosome 17p, which removes the tumor-suppressor gene TP53. This is the highest-risk finding, associated with aggressive disease and shorter response to treatment.
• t(4;14): Translocation between chromosomes 4 and 14, activating the FGFR3 gene. Responds to bortezomib (which partially overcomes this risk) and benefits from quadruplet therapy.
• t(14;16) and t(14;20): Less common translocations associated with high risk.
• gain(1q21): Gain of chromosome 1q21, now considered high-risk (especially with ≥4 copies). Present in ~40% of cases; increasingly recognized as a target for novel therapies.

Standard-risk cytogenetics include: t(11;14) (associated with good response to venetoclax), trisomies (hyperdiploidy, the most common and favorable change), and t(6;14). Patients with standard-risk myeloma are expected to have very good outcomes with modern therapy.

Double-hit and triple-hit myeloma: Patients who have two or more high-risk cytogenetic changes (e.g., del[17p] + t[4;14]) are called “double-hit” or “triple-hit.” These patients have significantly worse outcomes with standard regimens and should be enrolled in clinical trials whenever possible. Intensified maintenance (daratumumab + lenalidomide rather than lenalidomide alone) is often recommended in this group.

Not all newly diagnosed myeloma requires immediate treatment. “Smoldering multiple myeloma” (SMM) is a precursor state — myeloma cells are present and producing M-protein, but have not yet caused CRAB organ damage or met the SLiM threshold criteria. Some patients live with SMM for years without it progressing to active myeloma requiring treatment.

Why not treat all SMM? Studies have shown that treating all SMM patients does not improve outcomes compared to careful monitoring, because many patients progress very slowly and could be exposed to years of drug side effects and costs unnecessarily. The IMWG has developed a risk stratification model that separates high-risk from low-risk SMM based on M-protein level, free light chain ratio, and bone marrow plasma cell percentage.

High-risk SMM: Patients with high-risk SMM (2-year progression risk >50–70%) are now being studied in clinical trials comparing early treatment to active surveillance. The QUIREDEX trial (Spain) and several US trials showed a progression-free survival benefit for early treatment in high-risk SMM. In 2024, the FDA approved isatuximab (Sarclisa) for high-risk SMM based on the ITHACA/AQUILA trial data, making it the first treatment specifically approved for SMM in the US. Discussion with a myeloma specialist is essential for high-risk SMM to decide whether early treatment is appropriate.

Low- and intermediate-risk SMM: Standard recommendation is active surveillance every 3–6 months with blood and urine M-protein monitoring, free light chain assay, CBC, and renal function tests. Annual or symptom-triggered whole-body MRI (or PET-CT) to check for early bone lesions or extramedullary disease. No treatment is started until CRAB or SLiM criteria are met, or the 2-year progression risk is high.

Practical note: Receiving a diagnosis of smoldering myeloma can be psychologically challenging — you know you have a form of cancer but are asked to wait without treatment. This is a medically justified approach, not a doctor ignoring a problem. Many patients benefit from connecting with a myeloma patient community and having a clear action plan for what symptoms or lab changes would trigger treatment.

Imaging is essential in myeloma — both to detect bone lesions at diagnosis and to monitor for disease response or progression during treatment. However, different imaging technologies have very different sensitivities, and understanding which test is being ordered and why helps you participate in shared decision-making.

Whole-body low-dose CT (WBLD-CT): This is the current first-line imaging recommendation from IMWG for initial staging. It detects osteolytic lesions much better than conventional X-ray skeletal surveys (15–20% better sensitivity), takes only 5–10 minutes, and produces much lower radiation than a diagnostic CT. It does NOT show bone marrow involvement directly (only bone destruction); a 3mm punch-out hole may be missed. It is excellent for rib fractures, vertebral fractures, and large lytic lesions.

Whole-body MRI (WB-MRI): The most sensitive modality for bone marrow infiltration — it detects diffuse and focal bone marrow myeloma even before lesions destroy bone. Recommended by IMWG when WBLD-CT is negative but clinical suspicion remains high, or as baseline staging at specialized centers. Takes 60–90 minutes; no radiation. Excellent for spinal canal compromise and assessing risk of cord compression. Used to evaluate SLiM criterion (>1 focal lesion on MRI) that indicates treatment even without CRAB criteria.

PET-CT (FDG-PET with CT): PET uses a radioactive glucose tracer to detect metabolically active myeloma cells. Particularly useful for: detecting extramedullary disease (myeloma outside the bone marrow), assessing disease activity in difficult-to-evaluate areas, monitoring response to therapy (metabolic response precedes structural bone healing), and detecting early relapse. PET-negativity after treatment is a powerful favorable prognostic marker. Not used for diagnosis alone (false positives in inflammatory conditions); used in conjunction with bone marrow biopsy and serum markers. Radiation exposure is moderate (~7–10 mSv).

Plain X-ray skeletal survey: Previously the standard imaging test for myeloma, now largely replaced by WBLD-CT in most centers. X-ray misses approximately 30% of lytic lesions (only detects lesion after >30% bone mineral loss). Still used in resource-limited settings and when CT is not available. If your imaging is described as a “bone survey” or “skeletal survey,” ask whether WBLD-CT is available instead.

After treatment: how bone heals (or doesn’t): Unlike solid tumors where treatment response shows as shrinking of a mass, myeloma bone lesions rarely “fill in” structurally even after successful myeloma treatment. The lytic holes remain visible on X-ray and CT for years or decades, even in deep remission. This does NOT mean the treatment isn’t working. Response assessment in myeloma relies primarily on blood and urine markers (M-protein, free light chains) and bone marrow biopsy/MRD testing, not on bone healing on imaging. PET-CT metabolic activity is the exception — a metabolically active lesion becoming PET-negative does indicate treatment response.

A bone marrow biopsy (BMB) is among the most important and anxiety-provoking procedures in myeloma care. Understanding what is done, why, and what the results mean can significantly reduce the fear associated with it.

The procedure: A bone marrow biopsy involves collecting a small sample of bone and liquid marrow from inside the bone, typically from the posterior iliac crest (the back of the hip bone). The procedure takes 10–20 minutes and is done in an outpatient setting with local anesthesia. Most patients experience:

• A pressure sensation when the needle enters the bone — not usually described as sharp pain because local anesthetic numbs the outside tissue well (though not the marrow itself)
• A brief, sharp aspiration pain lasting 1–2 seconds when liquid marrow is drawn (aspiration)
• A core biopsy taken with a slightly larger needle; this may produce brief cramping pressure
• Soreness at the biopsy site for 1–3 days afterward, manageable with acetaminophen

Procedures vary by provider; some hematologists now offer IV sedation or nitrous oxide (laughing gas) as anxiolytics, which many patients find helpful. Ask your team about your options if you are particularly anxious.

What the biopsy tells us: The core biopsy (the solid cylinder of bone and marrow) reveals the architecture of the bone marrow — how much of it is replaced by plasma cells, whether the cells form aggregates or sheets, and how the bone structure looks. The aspirate (liquid marrow) provides individual cells for:

• Flow cytometry: Identifies the percentage of plasma cells and their phenotype (whether they’re normal or abnormal)
• Cytogenetics (conventional karyotype): Looking for chromosomal abnormalities in cultured cells
• FISH (fluorescence in situ hybridization): The most sensitive method for detecting specific myeloma-relevant chromosomal changes (del17p, t[4;14], 1q gain, etc.) — this is done on interphase cells, not just dividing cells
• MRD testing (NGS or flow cytometry): After treatment, the aspirate is sent for clonoSEQ or multiparameter flow to assess residual disease

Why it’s repeated: You will typically have a bone marrow biopsy at: (1) initial diagnosis; (2) after completing induction therapy (to assess response and MRD before transplant); (3) 100 days after transplant; (4) during maintenance if clinical remission milestones are assessed; (5) at suspected relapse. Each biopsy serves a distinct clinical purpose. If your doctor wants a repeat biopsy, it is not because anything has necessarily gone wrong — it is part of the protocol to understand the depth of your response and guide the next treatment phase.

Complications: Serious complications are rare (<0.1%). Bleeding at the site (managed with manual pressure), infection, and nerve injury have been reported but are uncommon. Patients on anticoagulants may need to hold them temporarily — discuss with your team 5–7 days before the procedure.

For the past decade, the standard of care for newly diagnosed myeloma was a three-drug regimen: a proteasome inhibitor (bortezomib), an immunomodulatory drug (lenalidomide), and dexamethasone — together called VRd. In the last few years, trials have shown that adding a fourth drug, the anti-CD38 antibody daratumumab (Darzalex), significantly improves outcomes. The combination of daratumumab + VRd (Dara-VRd) is now preferred for most eligible patients.

Why daratumumab works so well in combination: Daratumumab attaches to a protein called CD38, which is found in very high amounts on myeloma cells. It kills myeloma cells through multiple immune mechanisms: antibody-dependent cellular cytotoxicity (ADCC), complement activation, and by depleting immunosuppressive regulatory T cells (T-regs and Myeloid-derived suppressor cells) that help myeloma evade the immune system. In combination with VRd, daratumumab improves the depth of response — more patients achieve MRD-negativity (undetectable residual disease) compared to VRd alone.

The GRIFFIN and PERSEUS trials: The GRIFFIN trial (transplant-eligible) showed improved stringent complete response rates with Dara-VRd vs VRd. The PERSEUS trial (also transplant-eligible) showed significant improvement in progression-free survival (PFS) with Dara-VRd induction + ASCT + Dara-VRd consolidation + Dara-R maintenance vs the standard VRd approach (4-year PFS: 84% vs 68%). Based on PERSEUS, Dara-VRd is now FDA-approved and recommended as the standard frontline regimen for transplant-eligible patients. For transplant-ineligible patients, the MAIA trial established Dara-Rd (daratumumab + lenalidomide + dexamethasone) as a highly effective standard.

What Dara-VRd involves practically: Daratumumab is given by subcutaneous injection (since 2020, a subcutaneous formulation DARZALEX FASPRO with hyaluronidase replaced the 3–6 hour IV infusion, making administration much more convenient — 3–5 minutes injection time). Bortezomib is given by subcutaneous injection twice weekly then weekly. Lenalidomide is taken as an oral pill. Dexamethasone is taken orally. The regimen involves several cycles (typically 4–6) of induction before transplant, then consolidation and maintenance phases.

Isatuximab-based quadruplets (Isa-KRd, Isa-VRd): Isatuximab (Sarclisa) is a second anti-CD38 antibody with a different binding site from daratumumab. The IKEMA trial established isatuximab + carfilzomib + dexamethasone (Isa-KRd) in relapsed myeloma; ongoing trials are evaluating Isa-KRd in frontline. For patients with high-risk cytogenetics, carfilzomib (a next-generation proteasome inhibitor with more potent proteasome blockade than bortezomib) may be preferred, giving rise to the Isa-KRd quadruplet option, although FDA approval in frontline is still pending for this combination.

Questions to ask about your quadruplet regimen:

• Is Dara-VRd recommended for my specific risk profile (cytogenetics, age, kidney function)?
• Will I receive daratumumab as the subcutaneous injection or IV infusion?
• Are there clinical trials testing even more intensive approaches (five-drug, CAR-T upfront) that I might qualify for?
• What is the plan for maintenance therapy after transplant?

Lenalidomide (Revlimid) is one of the most important drugs in myeloma treatment, used in induction, maintenance, and relapsed disease. However, it requires participation in a mandatory safety program called REVLIMID REMS (Risk Evaluation and Mitigation Strategy) because of its serious teratogenicity (it causes severe birth defects identical to thalidomide, from which it is derived). Every patient taking lenalidomide — regardless of gender or reproductive status — must be enrolled in the REMS program and receive monthly counseling before each refill.

What REMS enrollment involves: Registration through the 1-800-4-CELGENE (now Bristol Myers Squibb) REMS portal. Men must agree to use contraception (lenalidomide can be present in semen). Women of childbearing potential must use two forms of contraception simultaneously, have monthly pregnancy tests, and confirm these before each 28-day refill. Post-menopausal women and men may need to submit confirmation of their status. The pharmacist cannot dispense lenalidomide without a REMS authorization number for each refill — this is non-negotiable and will delay your treatment if not handled proactively.

Lenalidomide-related side effects to monitor: Deep vein thrombosis (DVT) and pulmonary embolism (PE) — risk is approximately 5–8% per year, mitigated by anticoagulant prophylaxis (aspirin for standard-risk, low-molecular-weight heparin or direct oral anticoagulants for high-risk patients). Myelosuppression (low blood counts — particularly neutropenia requiring growth factor support). Second primary malignancies (SPMs) — a small but documented increased risk of certain solid tumors and blood cancers (MDS, AML) with long-term lenalidomide maintenance; the benefit of maintenance still outweighs this risk in clinical trials. Diarrhea and skin rash (usually manageable).

Lenalidomide vs. pomalidomide vs. thalidomide: These three agents are all “immunomodulatory drugs” (IMiDs) that work by binding Cereblon, which then degrades proteins (Ikaros and Aiolos) needed by myeloma cell proliferation. Lenalidomide is the standard for most newly diagnosed and earlier relapsed patients. Pomalidomide (Pomalyst) is used in later lines when lenalidomide is no longer effective. Thalidomide is rarely used now in the US due to toxicity, though it remains in use in some countries. The REMS requirements apply to all three agents.

Starting myeloma treatment can feel overwhelming. Knowing what each drug does, what schedule you’ll follow, and what side effects to monitor makes the process more manageable. Here is what a typical induction cycle looks like for the most common regimen, Dara-VRd (or VRd without daratumumab).

The typical 21-day or 28-day cycle: Most induction regimens run in cycles of 21 or 28 days. For Dara-VRd, a typical 21-day cycle might include:

• Day 1, 4, 8, 11 (some schedules): Bortezomib SC injection at the clinic or done by a home nurse. Takes about 10 minutes. Common immediate effects: mild burning/redness at injection site. Cumulative effects: peripheral neuropathy (tingling/numbness in hands/feet, building over several cycles).
• Days 1–14 or 1–21: Lenalidomide (oral pill) taken at home. Take at same time each day. The most important side effects to watch: fatigue, diarrhea/constipation, low blood counts (checked by bloodwork every 1–2 weeks), and deep vein thrombosis (daily aspirin or blood thinner prescribed). Avoid grapefruit juice (inhibits metabolism).
• Days 1, 2, 8, 9, 15, 16 (or similar): Dexamethasone (oral steroid). Taken on the mornings of bortezomib days. Dexamethasone causes: insomnia the night after taking it (expect this — it is nearly universal, not a sign something is wrong), increased appetite, mood changes (some people feel energized and anxious), and elevated blood sugar (diabetics need increased glucose monitoring). The high-dose dexamethasone schedule is 40 mg; if side effects are intolerable, it may be reduced to 20 mg.
• Daratumumab (first cycle): In the first cycle, daratumumab is given weekly as a subcutaneous injection. Premedication (antihistamine, acetaminophen, corticosteroid) is given before each injection to reduce infusion/injection reactions. Common reactions: local site redness/itching (more common with SC formulation than IV). Systemic reactions (flushing, runny nose, cough) can occur, mainly with the first administration. Reactions are monitored for 30–60 minutes after the first injection.

Bloodwork schedule: During induction, you will have blood tests every 1–2 weeks to monitor blood counts, kidney function, liver function, and electrolytes. M-protein and free light chain assays are typically checked every cycle to assess treatment response. More frequent monitoring occurs in the first weeks and if counts are low.

What a “response” looks like: The goal of induction is to reduce M-protein (the monoclonal protein produced by myeloma cells) by as much as possible before transplant. You will hear your oncologist use terms like:

• Partial Response (PR): ≥50% reduction in M-protein
• Very Good Partial Response (VGPR): ≥90% reduction in M-protein
• Complete Response (CR): No detectable M-protein on serum immunofixation + <5% plasma cells in bone marrow
• Stringent Complete Response (sCR): CR + normal free light chain ratio + no clonal cells in bone marrow by immunohistochemistry
• MRD-negative: No detectable myeloma cells by next-generation sequencing at sensitivity of 10&sup-;5 or 10&sup-;6

Achieving at least VGPR before transplant, and CR/sCR after transplant, are the treatment goals that most strongly predict long-term outcomes.

Managing day-to-day life during induction: Most patients can remain active during induction, though energy levels vary. Light to moderate exercise (walking, yoga, stationary cycling) is safe and beneficial — studies show it reduces fatigue. Avoid live vaccines. Practice careful hand hygiene. Avoid crowds during neutrophil nadir periods (usually days 10–14 of a 21-day cycle). If you develop fever, chills, severe bone pain, vision changes, or severe breathing difficulties at any time during treatment, call your care team immediately — do not wait for your next appointment.

For transplant-eligible patients, stem cell collection (called mobilization and apheresis) is done after completing induction therapy. Your own stem cells (hematopoietic stem cells — the cells that can regenerate your entire blood system) are harvested from your blood, frozen, and stored for later use in the transplant. Understanding this process helps you prepare for a key phase of your myeloma journey.

Step 1 — Mobilization (getting stem cells into the bloodstream): Stem cells normally live in the bone marrow, not the blood. To collect them, they must first be mobilized (pushed) into the circulation. This is done using one or more of the following:

• G-CSF (Neupogen/filgrastim or Neulasta/pegfilgrastim): A growth factor given by subcutaneous injection daily for 4–5 days that stimulates the bone marrow to produce stem cells and release them into the blood. Can cause significant bone aching (as the bone marrow becomes very active and expands) — this is the most common side effect and is managed with acetaminophen. Loratadine (Claritin) taken the day before and during G-CSF injections has been shown to reduce bone pain.
• Plerixafor (Mozobil): A CXCR4 receptor antagonist that directly dislodges stem cells from the bone marrow by blocking the anchor that holds them there. Usually combined with G-CSF in patients whose stem cell counts don’t rise adequately with G-CSF alone, or given upfront to everyone at many centers for more reliable mobilization. Given as a single subcutaneous injection ~11 hours before apheresis collection.
• Chemomobilization (cyclophosphamide + G-CSF): Some centers use a cycle of cyclophosphamide followed by G-CSF; this can produce very high stem cell yields but involves a period of low blood counts and higher infection risk. Less common now that plerixafor is widely available.

Step 2 — Apheresis (collecting the stem cells): When stem cell counts in the blood are high enough (usually monitored by daily CD34+ cell count after day 4 of G-CSF), you undergo apheresis. This procedure:

• Takes 3–5 hours in an outpatient apheresis center or blood bank
• Uses a machine that draws blood, separates stem cells through a centrifuge, and returns the remaining blood components to you
• Requires either two large peripheral IV lines or a central apheresis catheter (placed under local anesthesia if peripheral veins are inadequate)
• Common side effects: tingling/muscle cramps from citrate anticoagulant (treated with oral calcium), fatigue, mild lightheadedness
• Goal: collect ≥2 million CD34+ cells per kilogram body weight for one transplant (more if two transplants are planned)

How long your stem cells are stored: Collected stem cells are cryopreserved (frozen at –196°C) in liquid nitrogen and can be stored for many years without losing viability. This means that if your transplant is delayed, the cells will still be viable when you are ready. Stored cells can also be used for a second transplant (tandem transplant) or a salvage transplant at relapse.

Why collect more than you need right now: Recommendations suggest collecting enough cells for two transplants (typically ≥4 million CD34+/kg) even if only one is planned, because having a reserve provides the option for: salvage transplant at first or second relapse, or tandem transplant if your myeloma is high-risk. More is always better; collection efficiency varies by center, and it is much easier to collect cells when your disease is in deep remission early in treatment than later.

CAR-T (chimeric antigen receptor T-cell) therapy is one of the most significant advances in myeloma treatment in the last decade. Two CAR-T products are FDA-approved for relapsed/refractory myeloma: idecabtagene vicleucel (ide-cel, Abecma, Bristol Myers Squibb) and ciltacabtagene autoleucel (cilta-cel, Carvykti, J&J/Legend Biotech). Both target BCMA (B-cell maturation antigen), a protein found in high amounts on myeloma cells.

How CAR-T works: Your own T cells (immune fighter cells) are collected from your blood by a process called leukapheresis. These cells are sent to a manufacturing facility where they are genetically modified to express a chimeric antigen receptor — a protein that recognizes BCMA on myeloma cells. After manufacturing (4–8 weeks), the engineered cells are infused back into your bloodstream following a short course of lymphodepleting chemotherapy (cyclophosphamide + fludarabine). The CAR-T cells then multiply in your body and hunt for myeloma cells.

What to expect:

• Leukapheresis (collection): A 3–5 hour outpatient procedure where blood is drawn, T cells collected by a cell separator, and remaining blood components returned. Mild muscle cramping and tingling from citrate anticoagulant is common. You may need a central line (apheresis catheter) if vein access is limited.
• Bridging therapy: In the 4–8 weeks while your CAR-T cells are being manufactured, your team will manage the myeloma with “bridging” treatment to prevent rapid progression.
• Conditioning chemo: A 3-day inpatient course of lymphodepleting chemotherapy to create “space” for the CAR-T cells.
• CAR-T infusion: Typically a one-time outpatient or inpatient infusion. You will be observed for at least 7 days in or near the infusion center for early side effects.
• Monitoring period: Minimum 28 days of monitoring within 2 hours of a certified emergency facility (due to risk of late cytokine release syndrome or neurological events).

Cytokine release syndrome (CRS): The most common and expected side effect. As CAR-T cells multiply and kill myeloma cells, they release inflammatory cytokines causing flu-like symptoms (fever, low blood pressure, low oxygen). CRS is graded from mild (Grade 1: fever only, treated with acetaminophen) to severe (Grade 3+: requiring ICU care). Most CAR-T CRS in myeloma is Grade 1–2 and resolves with tocilizumab and supportive care. Your team will be monitoring continuously for this.

Neurotoxicity (ICANS): Immune effector cell-associated neurotoxicity syndrome can cause confusion, word-finding difficulty, headache, and rarely seizures. This is managed with corticosteroids. Cilta-cel has been associated with rare but serious delayed neurotoxicity (movement disorders, cranial nerve palsy) in some patients, which your team will review with you during the consent process.

Deep and durable responses: Cilta-cel in the KarMMa-3 and CARTITUDE-4 trials demonstrated progression-free survival superiority over standard regimens. Overall response rates of 70–98% have been reported in various trials, with complete response rates of 40–70%. The key advantage is durability — many patients achieve long remissions, and in some cases, sustained MRD-negativity even years after infusion.

Bispecific antibodies are a newer class of immunotherapy that works differently from CAR-T. Rather than requiring your own T cells to be collected and engineered, bispecific antibodies are “off-the-shelf” drugs that are manufactured in advance and can be given immediately. Three bispecific antibodies are now FDA-approved for relapsed/refractory myeloma:

• Teclistamab (Tecvayli, J&J): Targets BCMA on myeloma cells and CD3 on T cells simultaneously, physically linking them together so the T cell destroys the myeloma cell. Given by weekly (then biweekly) subcutaneous injection. Overall response rate in MajesTEC-1 trial: ~63% in triple-class-exposed patients.
• Elranatamab (Elrexfio, Pfizer): Also targets BCMA × CD3. Given weekly then biweekly. Approved for triple-class-exposed patients (BCMA-naive only). MagnetisMM-3 trial showed ~61% ORR.
• Talquetamab (Talvey, J&J): Unique: targets GPRC5D (a different myeloma surface protein) × CD3. Useful for patients whose myeloma has lost BCMA expression after prior BCMA-targeted therapy (CAR-T or belantamab). Weekly or biweekly SC injection. MonumenTAL-1 trial showed ~73% ORR. Distinctive side effects: dysgeusia (altered taste, metallic taste), nail changes, skin rash, weight loss related to the GPRC5D antigen being expressed in oral mucosa and skin.

CRS and ICANS with bispecifics: Similar to CAR-T but generally lower severity. Bispecifics require step-up dosing — starting at low doses and escalating to full dose over 1–2 weeks — during which the patient must be observed in a clinical setting for each step-up dose. After step-up is complete and no serious CRS/ICANS has occurred, patients can receive subsequent doses in outpatient settings. All three bispecifics require certified facilities with CRS/ICANS management capability.

Infection risk: All bispecific antibodies cause significant hypogammaglobulinemia (low antibody levels) because they deplete normal plasma cells along with myeloma cells. This requires regular intravenous immunoglobulin (IVIG) replacement therapy. Opportunistic infections (Pneumocystis jirovecii pneumonia, CMV reactivation, HSV/HZV reactivation) are real risks; prophylactic antibiotics, antivirals, and antifungals are used. Monitor for fever aggressively.

Comparing CAR-T vs. bispecifics: CAR-T requires manufacturing time (weeks) but offers potentially deeper, more durable responses and a finite treatment course (one infusion). Bispecifics are immediately available but require ongoing maintenance dosing (weekly injections continued until progression or toxicity). For patients needing rapid disease control, bispecifics may be preferable. For patients seeking a potential long remission without ongoing treatment, CAR-T may be preferred. Many myeloma programs are now using CAR-T and bispecifics in sequential or combination strategies.

Beyond the bispecific antibodies and CAR-T therapies described elsewhere, several other classes of drugs play important roles in relapsed myeloma.

Carfilzomib (Kyprolis) — next-generation proteasome inhibitor: Bortezomib and carfilzomib are both proteasome inhibitors, but carfilzomib binds irreversibly and is more potent. In patients whose myeloma is no longer responding to bortezomib, carfilzomib can overcome partial resistance. Regimens include Kd (carfilzomib + dexamethasone), KRd (carfilzomib + lenalidomide + dex), KCd (carfilzomib + cyclophosphamide + dex). Distinctive side effects: cardiovascular toxicity (hypertension, heart failure, dyspnea) requiring baseline cardiac assessment; less neuropathy than bortezomib. Infused IV over 30–60 minutes.

Ixazomib (Ninlaro) — oral proteasome inhibitor: The first oral proteasome inhibitor approved for myeloma. Taken as a once-weekly oral capsule in combination with lenalidomide and dexamethasone (IRd). Convenience is its main advantage — no injections or IV infusions required. Efficacy appears somewhat lower than IV PIs in head-to-head comparison. Neuropathy is less common than bortezomib. GI side effects (nausea, diarrhea) are more common. Used in 2nd line and later, and as an oral maintenance option at some centers.

Selinexor (Xpovio) — XPO1 inhibitor: Selinexor works through a completely different mechanism from all other myeloma drugs — it blocks the nuclear export protein XPO1, which prevents myeloma-promoting proteins from leaving the cell nucleus and forces tumor suppressor proteins to accumulate inside the nucleus. FDA-approved in two contexts: selinexor + bortezomib + dex (XVd) for patients with ≥1 prior line, and selinexor + dex (Sd) for heavily pretreated patients (5+ prior lines). Distinctive side effects: nausea (nausea prophylaxis is mandatory — ondansetron taken 30 minutes before selinexor), thrombocytopenia (low platelets), fatigue, and weight loss (appetite suppression). Taking selinexor with a fatty snack and the anti-nausea medications as prescribed dramatically reduces nausea.

Venetoclax (Venclexta) — BCL-2 inhibitor for t(11;14): Venetoclax is FDA-approved for CLL and AML with IDH2 mutation, but is also used off-label (with clinical trial or compassionate use) in myeloma patients with the t(11;14) translocation. In t(11;14) myeloma, BCL-2 protein is overexpressed, and venetoclax's ability to block BCL-2-mediated resistance to apoptosis results in response rates of 40–50% even in heavily pretreated patients. If your cytogenetics show t(11;14), ask your oncologist whether venetoclax is an option. The main risk is tumor lysis syndrome during initial dose escalation; careful ramp-up protocol with hydration and allopurinol is required.

Panobinostat (Farydak) — HDAC inhibitor: Approved for myeloma in combination with bortezomib and dex after ≥2 prior regimens. Less commonly used now given the proliferation of better-tolerated options. Significant GI toxicity (severe diarrhea) and cardiac QTc prolongation limit its use to patients who have exhausted better-tolerated options.

Multiple myeloma has been transformed by clinical trials over the past 15 years. Daratumumab, carfilzomib, pomalidomide, CAR-T, and every bispecific antibody were once investigational drugs available only through clinical trials. Enrolling in a trial is not a “last resort” — it is often the best way to access the most cutting-edge therapies before they become broadly available, especially for patients with relapsed disease.

Why myeloma trials are particularly important: Myeloma is a rapidly evolving field. The gap between what is available in clinical trials and what is accessible in standard practice can be 3–5 years. CAR-T with cilta-cel was FDA-approved in early 2022 after showing dramatic results in trials enrolling in 2018–2019. Bispecific antibodies became available in 2022–2023. Patients who enrolled in early trials of these agents in 2017–2020 had access to dramatically effective therapies years before community oncologists could prescribe them. Today’s trial drugs include: bispecific combinations, CAR-T products targeting GPRC5D and FcRH5, anti-CD38 next-generation antibodies, CELMoDs (cereblon E3 ligase modulators — next-generation IMiDs), and vaccine approaches to prevent relapse.

How clinical trials work in myeloma:

• Phase 1: First-in-human dose-finding studies. Small groups (typically 15–40 patients) receive escalating doses to determine safety and the maximum tolerated dose. May offer access to very novel agents years before approval.
• Phase 2: Larger groups (50–200+ patients), testing efficacy and safety at the established dose. Many pivotal bispecific trials were single-arm Phase 2s because the historical control response rates were well-established.
• Phase 3: Randomized controlled trials comparing new treatment to standard of care. The gold standard for regulatory approval. Usually 200–1000+ patients. Participation means 50% chance of receiving the experimental arm.

Finding trials:

• ClinicalTrials.gov (clinicaltrials.gov): The US government registry of all clinical trials. Search by condition (“multiple myeloma”), location (city or state), and status (“recruiting”). Provides eligibility criteria, treatment description, and contact information for each study.
• The International Myeloma Foundation (myeloma.org): Maintains a curated myeloma trial search tool that is more patient-friendly than ClinicalTrials.gov. Also has a free patient hotline (1-800-452-2873) staffed by myeloma patient navigators who can help identify appropriate trials.
• Your myeloma specialist: Academic and NCI-designated cancer centers typically have their own active trial portfolio. Ask at every visit: “Are there any active trials I might qualify for at this stage of my disease?”
• MMRF (Multiple Myeloma Research Foundation, themmrf.org): Strong patient advocacy organization with a trial finder and research programs.

Eligibility and practical considerations: Trials have strict eligibility criteria (prior lines of therapy, organ function, performance status). Don’t assume you don’t qualify without checking. Many trials require travel to a treating center; some have protocols that allow treating near home after initial enrollment. Costs of trial-related testing and the investigational drug itself are typically covered by the trial sponsor; standard-of-care costs are billed to insurance as usual (though coverage policies vary).

Questions to ask about a trial:

• Am I in the experimental or control arm? (Phase 3 only)
• What additional tests and visits are required beyond standard care?
• If I don’t respond or need to withdraw, what standard treatment options remain available?
• Is there a companion biomarker test needed before enrollment (e.g., BCMA expression level)?

Fertility preservation before treatment

High-dose melphalan (used in stem cell transplant) and many chemotherapy drugs can permanently damage the ovaries or testes, leading to infertility. If having biological children matters to you, raise this before treatment begins. Fertility specialists can often arrange egg, embryo, or sperm banking quickly so treatment delay is minimized.

• Egg or embryo freezing — most reliable option for women of reproductive age; typically takes 2–4 weeks
• Sperm banking — fast and reliable for men; should be done before any high-dose chemotherapy
• Ask your team for an urgent oncofertility referral — many myeloma programs have established pathways for this

Pregnancy during and after myeloma treatment

Pregnancy during active myeloma treatment is rare but carries serious risks. IMiD drugs (lenalidomide, thalidomide, pomalidomide) must be stopped immediately if a pregnancy occurs — contact your oncologist right away. Management requires collaboration with a maternal-fetal medicine specialist. After a good remission, some younger patients do go on to have successful pregnancies; discuss timing and safety with your oncologist well before trying to conceive.

Bone disease is among the most impactful and visible aspects of multiple myeloma. About 80% of patients have bone involvement at diagnosis. Protecting what bone you have — and allowing it to recover — is a critical and often underemphasized part of myeloma management.

Bone-protective agents (BPAs) — everyone on active therapy should have one:

• Zoledronic acid (Zometa): Monthly or quarterly IV infusion over 15–30 minutes. Inhibits osteoclasts (bone-destroying cells) and has modest direct anti-myeloma activity. Reduces skeletal-related events (SREs: fractures, need for radiation/surgery) by about 30–40%. FDA-approved for myeloma bone disease. Requires monitoring of kidney function before each dose; dose adjustment or withholding required if creatinine clearance is <35 mL/min.
• Denosumab (Xgeva): Monthly subcutaneous injection. A monoclonal antibody targeting RANK-L, the signaling protein that activates osteoclasts. Non-inferior to zoledronic acid for SRE prevention in myeloma; preferred in patients with renal impairment (no renal dose adjustment needed). FDA-approved for myeloma bone disease.
• Osteonecrosis of the jaw (ONJ): A rare but serious complication of both agents (incidence 1–2% overall; higher with longer duration). Preventative dental care — getting all needed dental procedures (extractions, implants, major dental work) completed before starting bisphosphonate or denosumab, and then avoiding invasive dental procedures while on therapy when possible — is critical. If you need urgent dental work while on a BPA, discuss with your oncologist about delaying your next infusion/injection. Notify all dentists that you are on a bone-protective agent.

Vertebroplasty and kyphoplasty for compression fractures: Vertebral compression fractures (VCFs) cause severe pain and loss of height. Kyphoplasty (balloon inflation to restore vertebral height before injecting bone cement) and vertebroplasty (cement injection without balloon) can provide rapid pain relief and stabilize crushed vertebrae. These procedures are done by interventional radiologists or spine surgeons. They are most effective when done soon after the fracture (within weeks) before the bone sets in a compressed position.

Radiation therapy for bone pain: Localized radiation (typically 8 Gy single fraction or 20–30 Gy in multiple fractions) provides rapid and effective pain relief for painful bone lesions that do not respond to systemic therapy. Radiation is not a substitute for systemic myeloma treatment but is an important tool for managing focal bone pain.

Calcium and vitamin D: Daily calcium (1,000–1,200 mg) and vitamin D (at least 1,000 IU/day, often 2,000+ IU/day to maintain vitamin D levels >30–40 ng/mL) are universally recommended to support bone health. High-dose vitamin D (50,000 IU weekly for 8–12 weeks) may be needed if baseline levels are severely deficient. Do NOT take calcium supplements without checking with your oncologist if you have hypercalcemia from myeloma itself.

Multiple myeloma is an immune-suppressing disease even before treatment begins, because the myeloma cells crowd out normal antibody-producing plasma cells. Treatment with steroids, proteasome inhibitors, IMiDs, anti-CD38 antibodies, CAR-T, and bispecifics each add additional immune suppression. Infections — particularly bacterial pneumonia, herpes zoster, and opportunistic infections — are a leading cause of morbidity and mortality in myeloma patients. Proactive prevention is as important as treating the myeloma itself.

Vaccines: what to get and when: Because myeloma and its treatments impair antibody production, vaccine responses may be reduced but are still worthwhile. Recommended vaccines for myeloma patients (confirm with your oncologist regarding timing relative to treatment):

• Annual inactivated influenza vaccine (flu shot — NOT the live attenuated nasal spray)
• COVID-19 booster (all currently authorized mRNA or protein subunit doses)
• Shingrix (recombinant zoster vaccine) — 2-dose series. Strongly recommended for all myeloma patients on therapy, because herpes zoster reactivation is common (especially with bortezomib, JAK inhibitors, and bispecifics). Shingrix is a non-live vaccine and can be given during chemotherapy, though ideally complete 2 doses before starting therapy if possible.
• Pneumococcal vaccines (PCV20 or PCV15 + PPSV23 per current ACIP guidance)
• Live vaccines (MMR, live varicella, yellow fever, live oral typhoid) are contraindicated during active myeloma treatment due to immune suppression risk.

Household contacts should be current with their vaccines to protect you from community exposure (cocooning strategy). Pneumovax and Shingrix should be offered to household contacts if not already completed.

Prophylactic medications: Your oncologist will often prescribe preventive antibiotics, antivirals, or antifungals based on your specific regimen. Common prophylaxis includes: antiviral (acyclovir or valacyclovir for herpes zoster prevention with bortezomib or daratumumab); antibiotic (trimethoprim-sulfamethoxazole for PCP pneumonia prevention with high-dose steroids or CAR-T); antifungal (fluconazole in some protocols). Do not stop these prophylactic medications without discussion with your care team, even if you feel well — the purpose is to prevent infections, not to treat them.

IVIG replacement: Patients with recurrent serious infections despite optimal therapy, or with severe hypogammaglobulinemia (IgG <400 mg/dL), may be given intravenous immunoglobulin (IVIG) infusions every 3–4 weeks. This temporarily replaces the antibodies your body cannot make, reducing infection risk. IVIG is a blood-derived product (pooled from thousands of donors) given by IV infusion over 2–4 hours.

When to seek immediate care: Any fever ≥38.3°C (101°F) in a myeloma patient on active therapy is a medical emergency until proven otherwise. Do not wait to see if it resolves on its own. Call your oncology team immediately or go to the emergency room. Febrile neutropenia (fever + low neutrophil count) requires prompt IV antibiotics. Have a low threshold for calling.

Fatigue is the most commonly reported symptom in myeloma — reported by 80–90% of patients during active treatment. It is caused by a combination of the disease itself (anemia, inflammatory cytokines), treatment side effects (particularly dexamethasone cycles, lenalidomide, bortezomib), sleep disruption from pain or steroid effects, and the psychological burden of living with a serious illness. Unlike normal tiredness, cancer-related fatigue doesn’t reliably improve with rest. But it can be managed.

The evidence for exercise: Multiple randomized trials in myeloma and hematologic cancers show that moderate aerobic exercise and resistance training during and after treatment:

• Reduce fatigue by 20–30% on validated fatigue scales
• Preserve and rebuild muscle mass lost during treatment (sarcopenia is common in myeloma)
• Improve balance and reduce fall risk (critical with myeloma bone disease)
• Reduce depression and anxiety scores
• May improve immune function and treatment response (mechanism not fully established)

The current evidence supports supervised exercise programs even during active treatment. Recommended activities include walking (30+ minutes most days), stationary cycling, resistance band or light weight training for upper and lower body, and yoga or stretching for flexibility and stress reduction. The key is consistency over intensity.

Activity precautions with myeloma bone disease: Not all exercise is safe for myeloma patients. High-impact activities (running, jumping, contact sports) increase fracture risk in bones with lytic lesions. Heavy weightlifting with spinal lesions can cause vertebral fractures. Always get clearance from your oncologist before starting or changing exercise habits. Exercises to avoid: spinal rotation or flexion with vertebral lesions, heavy lifting over the head with shoulder lesions, any activity where a fall could cause fracture. A physical therapist with oncology experience can design a safe, individualized program.

Sleep strategies: Dexamethasone causes insomnia in most patients on high-dose dex days (a single 40 mg dose keeps many patients awake all night). Strategies: take dexamethasone in the morning (not afternoon or evening), use sleep hygiene techniques (no screens 1 hour before bed, cool and dark room), consider short-term sleep medication discussion with your team if insomnia is severe. Melatonin (0.5–5 mg) is generally safe in myeloma, but confirm with your oncologist.

Addressing anemia: If fatigue is primarily driven by anemia (hemoglobin <10 g/dL), discuss with your team: erythropoiesis-stimulating agents (ESAs like darbepoetin) or, for severe acute anemia (Hgb <7–8), blood transfusion. Iron deficiency (common in myeloma patients) should be corrected. IV iron (ferric carboxymaltose, iron sucrose) is more effective than oral iron when GI absorption is impaired or inflammation is present.

Multiple myeloma treatment is among the most expensive in oncology. A full course of Dara-VRd induction followed by ASCT, consolidation, and indefinite lenalidomide maintenance can easily exceed $500,000 in drug costs alone in the US. Insurance coverage, copays, and out-of-pocket caps determine actual patient costs, but even covered patients often face substantial financial burden. Knowing the support programs available is critical.

Key patient assistance and copay programs:

• Darzalex/daratumumab (J&J/Janssen) — DARZALEX Access Program: Copay assistance for commercially insured patients; patient assistance program for uninsured/underinsured. 1-844-DARZALEX or darzalex.com/access.
• Revlimid/lenalidomide (BMS) — REVLIMID REMS Patient Assistance: BMS Patient Assistance Foundation provides free drug to qualifying patients with income ≤500% FPL. Copay program for commercially insured. 1-888-423-5436.
• Velcade/bortezomib (Takeda/generics available): Millennium Oncology Access Program. Generic bortezomib is now available from multiple manufacturers at substantially lower cost; ask your pharmacy if you are receiving brand-name Velcade.
• Abecma/ide-cel (BMS) and Carvykti/cilta-cel (J&J): CAR-T financial assistance programs exist; contact manufacturer patient support lines. These programs are complex because CAR-T involves hospitalization and administration costs beyond just the drug.
• Tecvayli/teclistamab, Talvey/talquetamab, Elrexfio/elranatamab (J&J and Pfizer): Patient support programs available; contact manufacturers directly.

The Patient Advocate Foundation and Co-Pay Relief Program: For patients who do not qualify for manufacturer PAPs or need help paying copays when manufacturer cards cannot be used (e.g., Medicare patients), the Patient Advocate Foundation Co-Pay Relief Program (copays.org) provides direct financial assistance for drug copays. The International Myeloma Foundation (myeloma.org) also maintains a financial resource database. HealthWell Foundation and PAN Foundation provide disease-specific myeloma grants.

Medicare patients: Manufacturer copay cards are not available to Medicare beneficiaries (federal anti-kickback regulations). Medicare Extra Help (Low Income Subsidy), Medicare Advantage plans with drug coverage, and state-specific pharmaceutical assistance programs (SPAPs) are alternative resources. Social workers at your cancer center can help identify which programs you qualify for — ask to speak with a financial counselor or social worker at your first visit.

Clinical trials as a financial option: Clinical trials often cover the cost of investigational drugs and trial-related testing. For patients with refractory myeloma or limited insurance coverage, enrollment in a clinical trial can provide access to cutting-edge therapy at reduced or no cost. Ask your myeloma team about active trials at every visit, particularly as you approach a new line of therapy.

There is no specific “myeloma diet” proven to slow the disease, but evidence-based nutrition and activity guidance can meaningfully improve your treatment tolerance, energy, and quality of life — and certain supplements interact with myeloma drugs in ways you must know about before taking them.

General nutritional priorities: Myeloma treatment creates several nutritional challenges. Dexamethasone in high doses causes protein catabolism (muscle breakdown), blood sugar spikes, and increased appetite. Bortezomib can cause nausea and peripheral neuropathy that makes cooking and eating difficult. Lenalidomide causes diarrhea or constipation in many patients. Given this context, evidence-based priorities include:

• Protein: High protein intake (1.2–1.5 g per kg of ideal body weight per day) supports muscle preservation during steroid-heavy regimens. Lean protein sources (poultry, fish, legumes, eggs, Greek yogurt) are preferred. A registered dietitian can help tailor this to your kidney function — patients with renal impairment have lower protein tolerance.
• Hydration: Critical for patients receiving bortezomib-based therapy and for those with light chain myeloma or renal involvement. Aim for 8–10 glasses of water daily unless told otherwise by your team. Adequate hydration reduces the risk of cast nephropathy worsening and helps flush metabolites. During dexamethasone days, blood sugar elevation increases urinary water loss; increase intake accordingly.
• Managing steroid-related blood sugar: Dexamethasone causes transient hyperglycemia peaking 6–8 hours after the dose, often resolving within 24–48 hours. A lower-glycemic diet (reducing simple carbohydrates, increasing fiber) on dexamethasone days can help. For patients who develop true steroid-induced diabetes, temporary insulin or metformin may be needed — discuss with your oncologist early rather than waiting for symptoms.
• Bone health and nutrition: Calcium and vitamin D are important for bone health in myeloma. However, hypercalcemia (elevated blood calcium from bone destruction) is common in active myeloma, and supplementation must be guided by your lab values. Do not take calcium supplements without knowing your current serum calcium level. Bisphosphonate therapy (zoledronic acid or denosumab) handles the bone resorption mechanistically; your team will guide supplement dosing accordingly.

Exercise: Multiple clinical trials, including the MASCOT study and the IMWG Physical Activity Working Group data, show that moderate aerobic and resistance exercise during myeloma treatment is safe (with appropriate precautions) and improves fatigue, muscle strength, quality of life, and potentially overall survival. Specific guidance:

• Aerobic exercise: 150 minutes per week of moderate intensity (brisk walking, stationary cycling, swimming). Start at lower intensity and build up; reduce on high-dose steroid days when fatigue from poor sleep is common.
• Resistance training: 2–3 sessions per week targeting major muscle groups. This is especially important for countering dexamethasone-induced muscle wasting. Start light and progress slowly.
• Bone precautions: Patients with lytic lesions, vertebral involvement, or osteoporosis should avoid high-impact activities (running, jumping), heavy lifting, and twisting movements that risk pathological fracture. Work with a physical therapist experienced in oncology to design a safe program. Yoga, aquatic therapy, and light resistance are typically safe.
• Platelet count check: Avoid contact sports or activities with fall risk when platelets are <50,000/μL. Review your current count before changing your exercise program after each cycle.

Supplements to avoid or use with caution:

• Curcumin (turmeric extract): May have anti-myeloma properties in laboratory studies, but clinical trial evidence is inconsistent. More importantly, curcumin is a potent P-glycoprotein and CYP3A4 inhibitor and can significantly increase or decrease blood levels of bortezomib, lenalidomide, and daratumumab. Do not take curcumin supplements without explicit guidance from your myeloma oncologist.
• Vitamin C (high-dose IV): High-dose IV ascorbic acid is promoted by some alternative medicine providers for cancer. Clinical evidence for myeloma efficacy is absent; it can cause oxalate nephropathy in susceptible patients and interfere with 24-hour urine M-protein measurements.
• Green tea extract / EGCG: EGCG inhibits bortezomib’s proteasome inhibition by binding the boronic acid pharmacophore — the mechanism is well-documented. Even moderate green tea consumption (2–4 cups/day) may reduce bortezomib efficacy. Avoid green tea supplements and limit dietary green tea during bortezomib therapy.
• St. John’s Wort: A potent CYP3A4 inducer that dramatically lowers blood levels of many myeloma drugs. Completely contraindicated with IMiDs and virtually all oral myeloma therapies. Check all herbal supplements with your pharmacist.
• Vitamin D: Commonly low in myeloma patients; modest supplementation (1,000–2,000 IU/day) is often appropriate in the context of bisphosphonate therapy and low serum levels, but confirm your 25-OH vitamin D level first. Avoid very high doses without monitoring.

Questions to ask your team about nutrition:

• My current calcium level — is it safe to take a calcium supplement?
• Am I a candidate for a referral to an oncology dietitian?
• Are there any supplements I am currently taking that might interfere with my treatment?
• What physical activity restrictions should I follow given my bone disease?